US$ 22.66
glp-1 agonists and anesthesia How should we approach patients on agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the Guidelines Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like Glucagon-Like Peptide-1 Agonists and General
Description
In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative feedback mechanism in normal rats

However, renal effects of GLP-1 in heart failure (HF) has not been elucidated

Berberine is not a GLP-1 agonist, though both compounds influence metabolic pathways
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide

Then, we will discuss the approaches that can increase the endogenous production of GLP-1 through various stimuli
